Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
ConclusionsFive-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin 1 might be associated with the efficacy of this treatment regimen.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study | Toxicology